Department of Anesthesiology, Istanbul Faculty of Medicine, Istanbul University, 34393 Istanbul, Turkey.
Institute of Experimental Medicine, Neuroscience, Istanbul University, 34393 Istanbul, Turkey.
Rev Neurosci. 2018 Jun 27;29(4):417-423. doi: 10.1515/revneuro-2017-0065.
Acute brain dysfunction associated with sepsis is a serious complication that results in morbidity and mortality. Intravenous immunoglobulin (IVIg) treatment is known to alleviate behavioral deficits in the experimentally induced model of sepsis. To delineate the mechanisms by which IVIg treatment prevents neuronal dysfunction, an array of immunological and apoptosis markers was investigated. Our results suggest that IVIgG and IgGAM administration ameliorates neuronal dysfunction and behavioral deficits by reducing apoptotic cell death and glial cell proliferation. IgGAM treatment might suppress classical complement pathway by reducing C5a activity and proapoptotic NF-κB and Bax expressions, thereby, inhibiting major inflammation and apoptosis cascades. Future animal model experiments performed with specific C5aR and NF-κB agonists/antagonists or C5aR-deficient mice might more robustly disclose the significance of these pathways. C5a, C5aR, and NF-κB, which were shown to be the key molecules in brain injury pathogenesis in sepsis, might also be utilized as potential targets for future treatment trials of septic encephalopathy.
与败血症相关的急性脑功能障碍是一种严重的并发症,可导致发病率和死亡率升高。静脉注射免疫球蛋白(IVIg)治疗已知可减轻实验性败血症模型中的行为缺陷。为了阐明 IVIg 治疗预防神经元功能障碍的机制,研究了一系列免疫和细胞凋亡标志物。我们的结果表明,IVIgG 和 IgGAM 的给药通过减少凋亡细胞死亡和神经胶质细胞增殖来改善神经元功能障碍和行为缺陷。IgGAM 治疗可能通过降低 C5a 活性和促凋亡 NF-κB 和 Bax 表达来抑制经典补体途径,从而抑制主要的炎症和细胞凋亡级联反应。未来使用特定的 C5aR 和 NF-κB 激动剂/拮抗剂或 C5aR 缺陷型小鼠进行的动物模型实验可能会更有力地揭示这些途径的意义。C5a、C5aR 和 NF-κB 被证明是败血症性脑病发病机制中的关键分子,也可能被用作败血症性脑病未来治疗试验的潜在靶点。